Misplaced Pages

Daunorubicin/cytarabine

Cytarabine
Daunorubicin
Combination of
Daunorubicin	Anthracycline
Cytarabine	Antimetabolite
Clinical data
Trade names	Vyxeos
Other names	CPX-351
AHFS/Drugs.com	Monograph
License data	US DailyMed: Vyxeos
Pregnancy category	AU: D
Routes of administration	Intravenous
ATC code	L01XY01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: WARNINGRx-only EU: Rx-only
Identifiers
CAS Number	1256639-86-7
KEGG	D11390

Daunorubicin/cytarabine, sold under the brand name Vyxeos, is a fixed-dose combination medication used for the treatment of acute myeloid leukemia. It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.

Medical uses

Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.

References

1. ^ "Vyxeos APMDS". Therapeutic Goods Administration (TGA). 15 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.
2. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
3. "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
4. ^ "Vyxeos (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension". DailyMed. 13 April 2021. Archived from the original on 29 March 2021. Retrieved 18 June 2022.
5. "Vyxeos liposomal EPAR". European Medicines Agency (EMA). 23 August 2018. Retrieved 25 May 2024.
6. Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P (June 2022). "CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML". Cancers. 14 (12): 2843. doi:10.3390/cancers14122843. PMC 9221356. PMID 35740508.
7. "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more". Medscape. Archived from the original on 15 August 2017. Retrieved 19 March 2019.
8. "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Archived from the original on 11 April 2019. Retrieved 30 December 2018.
9. Chen EC, Fathi AT, Brunner AM (2018). "Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML". OncoTargets and Therapy. 11: 3425–3434. doi:10.2147/OTT.S141212. PMC 6003284. PMID 29928134.
10. Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, et al. (October 2020). "CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia". Minerva Medica. 111 (5): 455–466. doi:10.23736/S0026-4806.20.07017-2. PMID 32955826. S2CID 221842680.

• Medicine

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antineoplastic drugs
• Combination cancer drugs
• Orphan drugs
• Antineoplastic and immunomodulating drug stubs